Navigation Links
Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Date:10/8/2009

BOSTON, Oct. 8 /PRNewswire-FirstCall/ -- Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials. PTK 0796 is the most advanced once-daily, oral and IV antibiotic with a spectrum that is broad enough for single-agent treatment of life threatening infections such as complicated skin and skin structure infections (cSSSI) and moderate to severe community acquired bacterial pneumonia (CABP), with activity against resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Streptococcus pneumoniae (MDRSP) and vancomycin-resistant enterococci (VRE).

Under the terms of the agreement, Novartis and Paratek will share responsibility and costs for worldwide development of PTK 0796, while Novartis will have the exclusive right to commercialize PTK 0796 on a worldwide basis. Paratek will be eligible to receive up to $485 million in payments, which include up-front and future milestone payments, and will also receive a royalty on net sales of PTK 0796 around the world.

"We are pleased to announce our collaboration with Novartis, which will allow us to develop and commercialize a significant advance in the treatment of resistant infections that are found in community and hospital in an expeditious manner," said Thomas J. Bigger, President and CEO of Paratek Pharmaceuticals. "PTK 0796 is the only once-daily, oral and IV MRSA-active compound in clinical development with a spectrum broad enough for single-agent treatment of cSSSI and CAP. This deal will also help us to bring PTK 0796 to the market without the need for additional financing in this currently challenging and unpredictable economic environment."

Wedbush PacGrow Life Sciences acted as an advisor to Paratek Pharmaceuticals in this transaction.

More on PTK 0796 and Bacterial Resistance

PTK 0796 was developed to address the growing problem of bacterial resistance to currently available antibiotics. In a study published in the Journal of the American Medical Association (JAMA), Dr. Monina Klevins and her colleagues found that invasive MRSA infections, an unfortunate complication of serious infections such as cSSSI, led to a projected 18,650 deaths in the U.S. in 2005; this is more than HIV/AIDS and tuberculosis combined. MRSA is just one example among several where bacteria have developed resistance during decades of antibiotic use, so that many of the standard antibiotic regimens relied upon until very recently are no longer effective, while the pipeline of replacement products that target antibiotic resistance is remarkably thin.

PTK 0796 represents a new class of antibiotics that has shown potent, broad-spectrum activity against multi-drug resistant and susceptible Gram-positive bacteria, Gram-negative, anaerobic and atypical bacteria. PTK 0796 has shown favorable safety and tolerability in more than a dozen clinical studies and more than 500 subjects and offers the convenience of a once-daily 30 minute IV infusion or pill treatment. Paratek and Novartis are developing PTK 0796 as a single-agent antibiotic therapy with IV/oral step-down option for the leading infections requiring hospitalization, such as cSSSIs and moderate to severe community-acquired bacterial pneumonia (CABP).

Prior to Phase 3 studies, Paratek conducted a Phase 2 study in cSSSI of a similar design with more than 200 patients. Positive results of this study were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last Fall. The Phase 2 study met its primary safety and tolerability endpoint, demonstrating no relevant differences between PTK 0796 and Zyvox® in incidence or pattern of adverse events (AEs). In the clinically evaluable population of patients (N=188), the clinical success rates were 98.0% and 93.2% for PTK 0796 and Zyvox®, respectively.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. is engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases, with a particular focus on the growing worldwide problem of antibiotic resistance. Paratek is advancing novel compounds that can circumvent or block bacterial resistance involving technology initially developed by Paratek co-founder Dr. Stuart Levy's laboratory at Tufts University School of Medicine, and licensed to Paratek. Paratek's lead compound, PTK 0796, is a broad-spectrum antibiotic derived from the tetracycline class with oral and IV formulations that are being developed for the treatment of the most common and serious hospital and community bacterial infections. PTK 0796 was previously licensed to Merck & Co., Inc. until this arrangement ended in 2007. Oral and IV formulations of PTK 0796 are being compared to Zyvox® in Phase 3 clinical studies to treat cSSSIs. Phase 3 studies in additional indications such as CABP are planned.

Outside of its tetracycline antibacterial program, Paratek has also identified small molecules that inhibit bacteria-specific transcription factors for Multiple Adaptational Response (MAR) genes which control bacterial virulence and resistance development.

Paratek is privately held and headquartered in Boston, Massachusetts, U.S. For more information about Paratek and its research and development initiatives, visit Paratek's website at http://www.paratekpharm.com.

SOURCE Paratek Pharmaceuticals, Inc.


'/>"/>
SOURCE Paratek Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
2. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
3. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
4. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec 2, 2016 Research and Markets has ... newsletter to their offering. ... , R&D Drug Pipeline ... proprietary R&D Drug Pipeline Database provides 24/7 online access to information ... the market and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... -- bioLytical Laboratories, un líder mundial en test rápidos de enfermedades ... Test , a los miembros de la Kenya Pharmaceutical Association. ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ... http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue invitada por la Clinton Health ...
(Date:12/2/2016)... SPRINGFIELD GARDENS, N.Y. , Dec. 2, 2016 /PRNewswire/ ... victims, will be included in the Emergency Response Training ... "We are very excited to have LifeVac become part ... Arthur Lih , Founder and CEO of LifeVac. "Having ... use LifeVac safely and effectively will help leverage our ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 04, 2016 , ... ... have new attractive animation styles with unique displacement design elements," said Christina Austin ... lower third designs. Choose from a variety of design styles that include both ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing of ... optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to design ... that people break or avoid bad techniques of brushing the teeth in order to ...
(Date:12/2/2016)... ... , ... Two years ago, Arizona State University students produced ... 1 million viewers and won numerous honors, including the region’s top Emmy and ... Cronkite School of Journalism and Mass Communication are following up their award-winning investigation ...
(Date:12/2/2016)... ... December 02, 2016 , ... More ... in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, ... funds for area students and operating support to UNCF-member institutions, including Miles College, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Center for Autism and Related Disorders (CARD) ... by autism spectrum disorder (ASD) and other developmental disabilities. The group, which is being ... and other caregivers the opportunity to share stories and advice, seek help, and continue ...
Breaking Medicine News(10 mins):